Literature DB >> 34318658

Near-Infrared Radiation-Assisted Drug Delivery Nanoplatform to Realize Blood-Brain Barrier Crossing and Protection for Parkinsonian Therapy.

Yao Liu1, Honghai Hong2, Jincheng Xue3, Jingshan Luo1, Qiao Liu4, Xiaojia Chen4, Yue Pan5, Jingwei Zhou1, Zeming Liu6, Tongkai Chen1.   

Abstract

Mitochondrial dysfunction, which is directly involved in Parkinson's disease (PD), is characterized by the production of reactive oxygen species (ROS) and aberrant energy metabolism. Thus, regulating mitochondrial function might be an effective strategy to treat PD. However, the blood-brain barrier (BBB) presents a significant challenge for the intracerebral delivery of drugs. Here, we synthesized a zeolitic imidazolate framework 8-coated Prussian blue nanocomposite (ZIF-8@PB), which was encapsulated with quercetin (QCT), a natural antioxidant, to treat PD. ZIF-8@PB-QCT exhibited superior near-infrared radiation (NIR) response and penetrated through the BBB to the site of mitochondrial damage guided by the photothermal effect. In the mice model of PD, the QCT released from ZIF-8@PB-QCT significantly increased the adenosine triphosphate levels, reduced the oxidative stress levels, and reversed dopaminergic neuronal damage as well as PD-related behavioral deficits without any damage to the normal tissues. Furthermore, we explored the underlying neuroprotective mechanism of ZIF-8@PB-QCT that was mediated by activating the PI3K/Akt signaling pathway. Thus, combined with noninvasive NIR radiation, the biocompatible ZIF-8@PB-QCT nanocomposite could be used to treat neurodegenerative diseases.

Entities:  

Keywords:  blood−brain barrier; natural product; neurodegenerative disease; noninvasive targeted delivery, neuronal mitochondria

Mesh:

Substances:

Year:  2021        PMID: 34318658     DOI: 10.1021/acsami.1c12675

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  8 in total

Review 1.  Nanomaterial Technology and Triple Negative Breast Cancer.

Authors:  Kai Hou; Zeng Ning; Hongbo Chen; Yiping Wu
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

2.  The Effect of Oxidative Stress and Memantine-Incorporated Reactive Oxygen Species-Sensitive Nanoparticles on the Expression of N-Methyl-d-aspartate Receptor Subunit 1 in Brain Cancer Cells for Alzheimer's Disease Application.

Authors:  Jung Sun Park; Taeyeon Kim; Dohoon Kim; Young-Il Jeong
Journal:  Int J Mol Sci       Date:  2021-11-15       Impact factor: 5.923

Review 3.  Natural Products and Nanotechnology Against Coronavirus Disease 2019.

Authors:  Ning Zeng; Xue Chen; Zeming Liu
Journal:  Front Chem       Date:  2022-02-10       Impact factor: 5.221

Review 4.  Anti-Parkinsonian Therapy: Strategies for Crossing the Blood-Brain Barrier and Nano-Biological Effects of Nanomaterials.

Authors:  Guowang Cheng; Yujing Liu; Rui Ma; Guopan Cheng; Yucheng Guan; Xiaojia Chen; Zhenfeng Wu; Tongkai Chen
Journal:  Nanomicro Lett       Date:  2022-04-15

5.  Ultrasmall Coordination Polymers for Alleviating ROS-Mediated Inflammatory and Realizing Neuroprotection against Parkinson's Disease.

Authors:  Guowang Cheng; Xueliang Liu; Yujing Liu; Yao Liu; Rui Ma; Jingshan Luo; Xinyi Zhou; Zhenfeng Wu; Zhuang Liu; Tongkai Chen; Yu Yang
Journal:  Research (Wash D C)       Date:  2022-07-18

Review 6.  Synthesis of Prussian Blue Nanoparticles and Their Antibacterial, Antiinflammation and Antitumor Applications.

Authors:  Danyang Li; Meng Liu; Wenyao Li; Qiang Fu; Liyang Wang; Enping Lai; Weixin Zhao; Kaile Zhang
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-21

7.  Hybrid biomimetic assembly enzymes based on ZIF-8 as "intracellular scavenger" mitigating neuronal damage caused by oxidative stress.

Authors:  Qing Li; Ruixia Feng; Zhaohui Chang; Xiaojun Liu; Hao Tang; Qian Bai
Journal:  Front Bioeng Biotechnol       Date:  2022-08-31

8.  Efficient Sustained-Release Nanoparticle Delivery System Protects Nigral Neurons in a Toxin Model of Parkinson's Disease.

Authors:  Qun Wang; Rui Ma; Piaoxue Liu; Guowang Cheng; Qi Yang; Xiaojia Chen; Zhenfeng Wu; Dongsheng Yuan; Tongkai Chen
Journal:  Pharmaceutics       Date:  2022-08-18       Impact factor: 6.525

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.